2026-09-16——
MSK and OpenEvidence partner to integrate OncoKB into OpenEvidence and OpenEvidence into MSK's Epic
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On September 16, 2026, Memorial Sloan Kettering Cancer Center and OpenEvidence announced a partnership integrating MSK's OncoKB precision oncology knowledge base into OpenEvidence for providers, and integrating OpenEvidence into MSK's Epic electronic health records workflow.
What happened
- Announced September 16, 2026 by Memorial Sloan Kettering Cancer Center and OpenEvidence.
- OncoKB annotations, including oncogenic effect, level of evidence, and associated therapies, will be surfaced within OpenEvidence alongside patient context.
- OpenEvidence will be integrated into MSK's Epic electronic health records workflow.
- In October 2021, OncoKB became the first and remains the only somatic cancer variant knowledge base to be partially recognized by the U.S. FDA, with levels of evidence aligned to the AMP, ASCO, and CAP joint consensus recommendation.
- More than half of U.S. hematologist-oncologists use OpenEvidence, according to the release.
- Spokespeople quoted include Debyani Chakravarty (Lead Scientist, OncoKB) and Anaeze Offodile (Chief Strategy Officer) at MSK, and Travis Zack (Chief Medical Officer) and Samyukta Mullangi (VP Clinical Strategy) at OpenEvidence.
Sources
- newswise.com — primary
- mskcc.org — party background
- aacrjournals.org — party background
- cnbc.com — party background
- businesswire.com — party background
Announced 2026-09-16 · Added to the register 2026-09-30